Omega Therapeutics IPO Presentation Deck
Corporate Overview
-$200M+
Gross proceeds raised since company
formation in 2017
-$130M
Cash and cash equivalents (as at 3/31/21)
At least 12 months
Expected cash runway based on current
clinical plans, including base deal IPO
proceeds
~100+
Patent applications filed to date across
the OMEGA platform
© 2021 Omega Therapeutics, Inc.
Premier Life Science Syndicate Partners
Capital from Flagship Pioneering, Joined by Invus, Fidelity Management & Research Company,
Funds and Accounts Managed by BlackRock, Cowen, and Others
Flagship
Pioneering COWEN
LIFESCI
VENTURE PARTNERS
LOGOS
CAPITAL
NIM
Monashee
MIRAE ASSET
INVESTMENT MANAGEMENT
SPHERA
octagon
TERRA
MAGNUM
INVUS
II
IRVING INVESTORS
Point 72
Omega has completed three successful private financing
rounds with leadership and participation by well-known life
sciences investors and strategic partners
30View entire presentation